0
Signin
countryflagCA

888-969-2592

RY 141.08 0.0851% TD 77.38 0.8077% SHOP 80.58 -5.633% CNR 174.21 0.0862% ENB 51.67 1.0364% CP 113.34 0.3808% BMO 128.16 0.5729% TRI 229.48 -0.0566% CNQ 104.59 -1.4046% BN 60.46 -0.0496% ATD 75.69 1.244% CSU 3736.3 -2.3672% BNS 65.67 0.1831% CM 67.55 0.5508% SU 54.79 -0.2549% TRP 52.78 1.1111% NGT 58.11 -0.7854% WCN 228.73 0.6778% MFC 35.6 1.1651% BCE 46.39 0.3461%

Eupraxia Pharmaceuticals Inc

Healthcare CA EPRX

3.96CAD
0.01(0.25%)

Last update at 2024-05-10T19:59:00Z

Day Range

3.953.98
LowHigh

52 Week Range

3.279.10
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -23.91722M -23.36955M -4.01064M -7.24058M -14.83301M
Minority interest 0.66M 0.38M -0.45389M -0.44045M -0.37602M
Net income -23.25937M -22.98961M -3.99720M -7.17614M -13.23198M
Selling general administrative 5.53M 8.41M 1.27M 3.01M 7.54M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.19M 0.11M 0.12M 0.20M 0.13M
Ebit -23.20393M -18.19966M -2.24619M -6.15853M -11.88379M
Ebitda -22.13558M -21.96133M -2.01220M -5.57485M -14.56501M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -23.23561M -20.96741M -2.24619M -6.15853M -14.31472M
Other operating expenses - - - - -
Interest expense 1.59M 1.30M 1.88M 1.46M 0.14M
Tax provision - - - - -
Interest income 0.67M 2.40M 0.00043M 0.01M 0.00111M
Net interest income -1.01904M -1.23096M -1.88121M -1.45174M -0.14107M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 23.20M 18.68M 2.25M 6.16M 14.31M
Cost of revenue - - - - -
Total other income expense net 0.31M -3.46091M 0.12M 0.37M -0.37722M
Discontinued operations - - - - -
Net income from continuing ops -23.91721M -23.36955M -4.01064M -7.24058M -14.83301M
Net income applicable to common shares -23.25937M -22.98961M -3.99720M -7.17614M -13.23198M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 25.88M 31.22M 1.45M 3.29M 2.91M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - - - - 1.43M
Total liab 13.02M 10.84M 23.12M 21.42M 14.34M
Total stockholder equity 12.86M 20.39M -21.20976M -17.69039M -11.05920M
Deferred long term liab - - - - -
Other current liab - 0.00501M 6.94M 6.80M 8.69M
Common stock 92.34M 80.71M 23.80M 23.55M 23.55M
Capital stock 92.34M 80.71M 23.80M 23.55M 23.55M
Retained earnings -97.44614M -74.18676M -51.19716M -47.19996M -40.02382M
Other liab - - 0.38M 0.50M -
Good will - - - - -
Other assets 0.00337M 0.03M - - -
Cash 24.74M 20.89M 0.15M 1.16M 0.82M
Cash and equivalents - - - - -
Total current liabilities 4.14M 2.27M 22.54M 20.67M 14.34M
Current deferred revenue - - - - -
Net debt - - 12.37M 10.47M 2.96M
Short term debt 0.00000M 0.00000M 17.57M 16.56M 10.61M
Short long term debt 0.11M 0.09M 12.52M 11.63M 3.79M
Short long term debt total - - 0.20M 0.25M -
Other stockholder equity 17.96M 13.86M - - -
Property plant equipment 0.70M 0.59M 0.32M 0.65M 0.44M
Total current assets 25.18M 30.60M 1.14M 2.64M 2.47M
Long term investments - - - - -
Net tangible assets 12.86M 20.39M -21.20976M -17.69039M -11.05920M
Short term investments 0.00000M 9.01M - - -
Net receivables 0.12M 0.43M 0.62M 1.35M 0.06M
Long term debt 10.30M 9.26M - - -
Inventory - - - - -
Accounts payable - - - - -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 0.70M 0.62M 0.32M 0.65M 0.44M
Capital lease obligations 0.14M 0.20M 0.25M 0.31M 0.00513M
Long term debt total 10.37M 9.40M 0.20M 0.25M 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 9.01M -9.00000M -9.00000M -9.00000M -9.00000M
Change to liabilities 1.78M -0.46748M 0.85M 0.31M 1.35M
Total cashflows from investing activities 8.70M -14.44982M 0.02M -1.89504M -0.14186M
Net borrowings -0.18518M 12.08M -0.39070M 7.40M 3.67M
Total cash from financing activities 13.52M 49.92M -0.62664M 7.40M 5.30M
Change to operating activities -0.02053M 0.07M 0.00291M 0.03M -0.04724M
Net income -23.25937M -22.98961M -3.99720M -7.17614M -13.23198M
Change in cash 3.84M 20.74M -1.00595M 0.33M -3.16668M
Begin period cash flow 20.89M 0.15M 1.16M 0.82M 3.99M
End period cash flow 24.74M 20.89M 0.15M 1.16M 0.82M
Total cash from operating activities -18.77643M -14.64163M -0.40378M -5.17101M -8.32028M
Issuance of capital stock 13.30M 37.83M - - 0.00000M
Depreciation 0.19M 0.11M 0.12M 0.20M 0.13M
Other cashflows from investing activities 9.01M -5.01815M -0.05669M -1.88556M -1.88556M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.31M 0.19M 0.73M 0.14M -0.20858M
Sale purchase of stock 13.71M 37.83M - 0.00000M 1.65M
Other cashflows from financing activities - 0.00000M -0.23595M -0.23595M -0.08719M
Change to netincome 2.22M 8.45M 1.89M 1.32M 3.69M
Capital expenditures 0.31M 0.43M 0.43M 0.00948M 0.14M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 2.07M -0.17626M 1.56M 0.48M 1.10M
Stock based compensation 2.02M 4.21M 0.23M 0.54M -
Other non cash items 1.16M 3.41M 1.69M 0.87M 2.08M
Free cash flow -19.08480M -15.07330M -0.40393M -5.18049M -8.46214M

Fundamentals

  • Previous Close 3.95
  • Market Cap140.91M
  • Volume7401
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-29.97965M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.53

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
EPRX
Eupraxia Pharmaceuticals Inc		 0.01 0.25% 3.96 - - - 8.40 -3.9163
FRX
Fennec Pharmaceuticals Inc		 0.82 6.48% 13.47 - 33.33 29.10 84.57 30.47 -23.3985
SVA
Sernova Corp		 0.01 2.78% 0.37 - - - 7.95 -4.4095
TH
Theratechnologies Inc.		 -0.05 2.92% 1.66 - 55.25 1.64 19.46 2.23 -11.7353
ONC
Oncolytics Biotech Inc		 -0.1 5.92% 1.59 - - - 4.00 -2.3144

Reports Covered

Stock Research & News

View All

Profile

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Eupraxia Pharmaceuticals Inc

2067 Cadboro Bay Road, Victoria, BC, Canada, V8R 5G4

Key Executives

Name Title Year Born
Dr. James A. Helliwell FRCPC, M.D. CEO & Director 1974
Mr. Bruce G. Cousins CPA, C.A., CPA Pres & CFO 1961
Dr. Amanda Malone Ph.D. Chief Scientific Officer 1981
Mr. Paul Anthony Brennan B.Sc., M.Sc. Chief Bus. Officer NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).